{"id":"intranasal-calcitonin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nasal irritation or rhinitis"},{"rate":"5-15","effect":"Nausea"},{"rate":"2-10","effect":"Flushing"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Hypocalcemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcitonin is a 32-amino acid peptide hormone that acts on calcitonin receptors present on osteoclasts and other bone cells. By binding to these receptors, it directly inhibits osteoclast activity and promotes osteoclast apoptosis, thereby reducing bone resorption. The intranasal formulation allows systemic absorption of the peptide to achieve therapeutic effects on bone metabolism.","oneSentence":"Intranasal calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase bone mineral density.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:38.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Paget's disease of bone"},{"name":"Hypercalcemia of malignancy"}]},"trialDetails":[{"nctId":"NCT03812991","phase":"PHASE4","title":"The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2019-07-01","conditions":"Pelvic Ring Fractures","enrollment":21},{"nctId":"NCT00754884","phase":"PHASE4","title":"Calcitonin in the Treatment of Fibromyalgia","status":"WITHDRAWN","sponsor":"Unidad de Investigacion en Enfermedades Cronico-Degenerativas","startDate":"2008-10","conditions":"Fibromyalgia","enrollment":""},{"nctId":"NCT00959764","phase":"PHASE3","title":"A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women","status":"COMPLETED","sponsor":"Tarsa Therapeutics, Inc.","startDate":"2009-06","conditions":"Osteoporosis, Postmenopausal","enrollment":565},{"nctId":"NCT00620854","phase":"PHASE2","title":"A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women","status":"COMPLETED","sponsor":"Tarsa Therapeutics, Inc.","startDate":"2008-02","conditions":"Osteoporosis","enrollment":24},{"nctId":"NCT00414973","phase":"PHASE3","title":"A Study for Patients With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-12","conditions":"Osteoporosis","enrollment":364},{"nctId":"NCT00444808","phase":"PHASE4","title":"Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs","status":"TERMINATED","sponsor":"Université de Montréal","startDate":"2007-02","conditions":"Rib Fractures, Pain","enrollment":19}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ARTHRITIS INFECTIVE"},{"count":1,"reaction":"CELLULITIS"},{"count":1,"reaction":"COMPRESSION FRACTURE"},{"count":1,"reaction":"HAEMATOCRIT DECREASED"},{"count":1,"reaction":"HAEMOGLOBIN DECREASED"},{"count":1,"reaction":"INCISION SITE ERYTHEMA"},{"count":1,"reaction":"INFLUENZA LIKE ILLNESS"},{"count":1,"reaction":"INTESTINAL DILATATION"},{"count":1,"reaction":"PRESYNCOPE"}],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Miacalcin and Miacalcic"],"phase":"marketed","status":"active","brandName":"Intranasal calcitonin","genericName":"Intranasal calcitonin","companyName":"Université de Montréal","companyId":"universit-de-montr-al","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intranasal calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase bone mineral density. Used for Osteoporosis in postmenopausal women, Paget's disease of bone, Hypercalcemia of malignancy.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}